MedTrace Logo

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

NCT05826535 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 270

Last updated 2026-05-20

No results posted yet for this study

Summary

This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of rondecabtagene autoleucel (ronde-cel) also known as LYL314, a dual-targeting chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 in participants with aggressive large B-cell lymphoma.

Conditions

Interventions

DRUG

Rondecabtagene autoleucel (ronde-cel)

CAR T-cell therapy

DRUG

Fludarabine

Conditioning chemotherapy

DRUG

Cyclophosphamide

Conditioning chemotherapy

Sponsors & Collaborators

  • Lyell Immunopharma, Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-09
Primary Completion
2028-12-31
Completion
2031-06-30
FDA Drug
Yes

Countries

  • United States
  • Australia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05826535 on ClinicalTrials.gov